secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2023-05-23T23:59:59+00:00
Accession:  0001193125-23-151834
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics repurchases 4.45M shares from Apeiron at $1.58/sh, ends proxy contest
--------------------------------------------------------------------------------

- Company to buy 4,454,248 shares from Apeiron Parties at $1.58/share, eliminating their entire beneficial ownership.
- Apeiron withdraws its March 2023 notice to nominate three directors for the 2023 annual meeting.
- Share repurchase does not change previously disclosed cash runway into second half of 2025.
- Standstill and voting agreement applies through the earlier of 4 years or 30 days before 2027 annual meeting.
- Company plans to initiate Phase 1/2 clinical trial of lead candidate SNS-101 in mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523151834/0001193125-23-151834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523151834/d488025d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-151834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer